281 results about "Medicine.oncology" patented technology

A new optimization method for generating treatment plans for radiation oncology is described and claimed. This new method works for intensity modulated radiation therapy (IMRT), intensity modulated arc therapy (IMAT), and hybrid IMRT.

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

The present invention provides stem cells loaded with bi-functional magnetic nanoparticles (nanoparticle-loaded stem cells (NLSC)) that both: a) heat in an alternating magnetic field (AMF); and b) provide MRI contrast enhancement for MR-guided hyperthermia. The nanoparticles in the NLSC are non-toxic, and do not alter stem cell proliferation and differentiation, the nanoparticles do however, become heated in an alternating magnetic field, enabling therapeutic applications for cancer treatment. NLSC can deliver hyperthermia to hypoxic areas in tumors for sensitization of those areas to subsequent treatment, thus delivering therapy to the most treatment-resistant tumor regions. The heating of diseased tissue either results in direct cell killing or makes the tumor more susceptible to radio- and/or chemotherapy. The NLSC of the present invention can be used for MR image-guided hyperthermia in oncology, in stem cell research for cell tracking and heating, and for elimination of mis-injected stem cells.

An apparatus and method for segmenting three-dimensional (3D) medical images containing a region of interest is provided that identifies a first set of seed points within the region of interest and a second set of seed points outside the region of interest. A first sphere is constructed within the region of interest. Voxels contained within the medical image are classified using a spatial constrained fuzzy clustering algorithm. A plurality of second spheres is generated. Ones of the plurality of second spheres are accepted that satisfy the homogeneity function threshold as defined by the spatial constricted fuzzy clustering algorithm. A three-dimensional area is grown that defines the region of interest. The region of interest defined by the three-dimensional area is displayed.

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.

A method and system facilitate communication with a patient on an outpatient oral oncology regimen. The method and system facilitate creating an initial contact guide to direct a patient interaction occurring at the beginning of the outpatient oral oncology regimen and using the initial contact guide to conduct an initial contact with the patient using the branching logic of the initial contact guide to determine which initial contact guide questions and informational scripts to present based on information provided by the patient. The method and system further facilitate creating a secondary contact guide to conduct a secondary, follow-up contact with the patient using the branching logic of the secondary contact guide to determine which secondary contact guide questions and informational scripts to present based on information provided by the patient.

The invention belongs to the fields of genetic engineering and oncology, and discloses a blood serum/blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof. The marker is formed by combining miR-451 and miR-490-3p. The marker and primers of the marker can be used for preparing a diagnostic kit and are used for the auxiliary diagnosis of pancreatic cancer.

The invention discloses a kit and a method for detecting 50 tumor-relevant hotspot mutation genes. According to the method, a capture method of 207 hotspot mutation regions of 50 relevant genes (including oncogenes and cancer suppressor genes) and a preparation method of a liquid-phase hybridization library used in capturing are researched aiming at oncology. The method particularly comprises the steps of selecting sequence information of 207 hotspot mutation regions, designing a PCR primer, preparing a biotin labeled liquid-phase hybridization library by virtue of a PCR method, hybridizing the biotin labeled liquid-phase hybridization library with a constructed target genome DNA library, and carrying out high-throughput sequencing and bioinformatics analysis on captured fragments, so as to obtain the mutation condition of nucleic acid sequence sites of a sample. By virtue of the method provided by the invention, high-quality sequencing data can be obtained, the relatively high capturing efficiency and the relatively good uniform capturing of the target sites can be realized, the disadvantages of low efficiency, poor uniformity and the like of solid phase hybridization are solved, and the sequencing cost is greatly lowered.

The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

The invention relates to a tumor interventional dose drainage treatment device, and belongs to the technical field of medical apparatuses and instruments. The tumor interventional dosing drainage treatment device comprises an intervention device storage cabinet, a hidden battery box, a drainage cabinet, and a dosing cabinet. The lower side of the intervention device storage cabinet is provided with a device fixing chassis. The device fixing chassis is internally provided with a charging wire storage cabin. The charging wire storage cabin is provided with a wire cabin door. The wire cabin door is connected with the charging wire storage cabin through a wire cabin door hinge. The charging wire storage cabin is internally provided with a wire winding roller. The wire winding roller is connected with the charging wire storage cabin through a wire roller rotating shaft. The wire winding roller is provided with a battery charging wire. The device is complete in functions and convenient in use. When the device performs interventional therapy of an oncology department and dosing, operation is simple, and the device saves time and efforts, and working difficulty of medical staff is reduced.

A computing system comprising a central processing unit (CPU), and memory coupled to the CPU and having stored therein instructions that, when executed by the computing system, cause the computing system to execute operations to generate a radiation treatment plan. The operations include accessing a minimum prescribed dose to be delivered into and across the target, determining a number of beams and directions of the beams, and determining a beam energy for each of the beams, wherein the number of beams, the directions of the beams, and the beam energy for each of the beams are determined such that the entire target receives the minimum prescribed dose. A quantitative time-dependent model-based charged particle pencil beam scanning optimization is then implemented for FLASH therapy.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

Systems, methods and apparatus are provided through which in some embodiments an integrated oncology diagnostic workflow system supports both multi-phase and multi-modality image acquisition and processing.

Image storage assemblies comprise thin metal screens adjacent phosphor storage screens. The thin metal screen is from about 0.01 to about 0.75 mm in thickness when composed of copper and from about 0.05 to about 0.4 mm when composed of lead. These image storage assemblies can be used in portal imaging whereby imaging radiation is directed through the thin metal screens before the phosphor storage screens. Stimulating radiation can then be directed to the phosphor storage screen before it reaches the thin metal screen.

A first objective of the present invention is to demonstrate a method for the detection and prognosis of cancer and of its metastatic potential. Preferably, the cancer is selected from breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, a sarcoma and a leukaemia, without being limited thereto. One aspect of the present invention consists of the use of the LIV21 complex as a prognostic indicator for cancer and in the therapeutic monitoring thereof. The LIV21 complex is defined in terms of the extract of proteins and peptides studied by Maldi and ESI MS/MS or Maldi Tof/Tof mass spectrometry. Said extract was obtained by attachment of the LIV21 complex to one of these LIV21 polyclonal antibodies. The LIV21 complex is also defined in terms of its overall mass spectrometry profile (FIG. 5) and the number and the molecular weight of the bands of protein extracts obtained as a function of the temperature to which the sample is subjected and the migration conditions described. Another aspect is the use of biochips for the pharmacodiagnosis of oncological pathologies and of neurodegeneration.

Embodiments of the invention provide systems and methods for managing oncology care plans. The systems and methods involve or include: retrieving a standard care plan from an electronically stored library of oncology care plans provided by one or more clinical content providers; receiving, from a user, a modification to the standard care plan; generating a local care plan that includes the standard care plan and the modification to the standard care plan; retrieving, from the electronically stored library of oncology care plans, an updated standard care plan that includes one or more updates to the standard care plan provided by the one or more clinical content providers; and automatically generating an updated local care plan that includes the updated standard care plan and the modification to the standard care plan.

The invention relates to a refrigeration medicine dual-purpose intervention therapeutic apparatus for the medical oncology, and belongs to the technical field of medical apparatuses and instruments. The refrigeration medicine dual-purpose intervention therapeutic apparatus comprises a multifunctional combined box, a therapeutic box supporting device and an on-off operation panel, wherein a combined box supporting plate is arranged on the lower side of the multifunctional combined box, a combined box lifting pushing column is arranged on the lower side of the combined box bearing plate, a combined box lifting pressure pump is arranged on the lower side of the combined box lifting pushing column, a push piston is arranged in the combined box lifting pressure pump, an anti-falling reinforcement bottom plate is arranged on the lower side of the combined box lifting pressure pump, and a foot-stepping type pressure pump switch is arranged on the right side of the anti-falling reinforcement bottom plate. The refrigeration medicine dual-purpose intervention therapeutic apparatus is complete in function and convenient to use; when the tumor intervention treatment is conducted, operation is easy and convenient, time and labor are saved, and the working difficulty of medical staff is lowered.

Biologically active cannabidiol analogs comprising a compound of the formula

wherein one of R₁ or R₂ or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R₁ or R₂ or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R₁ or R₂ (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

The invention provides a preparation method for a soluble truncated human tumor necrosis factor-related apoptosis inducing ligand (TRAIL) active protein, comprising the following steps of: (A) designing and synthetizing an oligomerization deoxyribonucleic acid (DNA) single-stranded segment according to the amino acid sequence of the human TRAIL protein issued by a Genebank by the preference of a bacterium genetic code; (B) synthetizing a complete double stranded DNA by three-time polymerase chain reaction (PCR); (C) carrying out amplification by utilizing a T-carrier, and inserting the amplified double stranded DNA segment into an expression carrier and screening a positive transformant; (D) expressing the truncated human TRAIL protein in escherichia coli at low temperature; (E) purifying the protein by using a three-step method; and (F) determining the truncated TRAIL protein. The invention realizes that the truncated human TRAIL protein is efficiently expressed in an escherichia coli cell and a purification preparation technique thereof and overcomes the problem that an infusible inclusion body is easy to form in the prior art. The method has the advantages of simple operation, short fermentation time and easy purification, and moreover, the protein is ensured not to have any modification, and the protein reaches electrophoretically pure. The invention can be directly used for the research work of biochemistry and molecular biology and the oncology and the preclinical stage of tumor treatment or the development of clinical drugs.